Stylized facts about innovation processes in modern biotechnology

The Economic Dynamics of Modern Biotechnology

Volumn , Issue , 2004, Pages 43-75

  McKelvey, Maureen ^a   Rickne, Annika ^a   Laage Hellman, Jens ^a  

^a CHALMERS UNIVERSITY OF TECHNOLOGY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84896227971     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.4337/9781845420611.00010     Document Type: Chapter

References (136)

1. Acharya, R. (1999), The Emergence and Growth of Biotechnology: Experiences in Industrialised and Developing Countries, Cheltenham, UK and Northampton, MA, USA: Edward Elgar.
2. Alm, H. (2002), 'The Swedish bio-pharma industry: how and why small- and medium-sized firms use collaboration in relation to innovation', paper presented at workshop The Economics and Business of Bio-Sciences & Bio-Technologies: What can be learnt from the Nordic Countries and the UK?, Chalmers University of Technology, Gothenburg, Sweden, 25-27 September.
3. Arora, A. and A. Gambardella (1990), 'Complementarity and external linkages: the strategies of the large firms in biotechnology', The Journal of Industrial Economics, XXXVIII(4), 361-79.
4. Audretsch,D. and M. Feldman (1996), 'R&D spillovers and the geography of innovation and production', American Economic Review, 86, 630-40.
5. Audretsch, D. and P. Stephan (1996), 'Company-scientist locational links: the case of biotechnology', American Economic Review, 86(3) 641-52.
6. Bartholomew, S. (1997), 'National systems of biotechnology innovation: complex interdependence in the global system', Journal of International Business Studies, 28(2), 241-66.
7. Baum, J.A.C., T. Calabrese and B.S. Silverman (2000), 'Don't go it alone: alliance network composition and startups' performance in Canadian biotechnology', Strategic Management Journal, 21, 267-94.
8. Braunerhjelm, P., D. Cetindamar and D. Johansson (2002), 'The support structure of the biomedical clusters in Ohio and Sweden', in B. Carlsson (ed.), Technological Systems in the Bio Industries: An International Study, Boston: Kluwer Academic Publishers.
9. Breschi, S. and F. Lissoni (2001), 'Knowledge spillovers and local innovation systems: a critical survey', Industrial and Corporate Change, 10(4), 975-1005.
10. Bud, R. (1993), The Uses of Life: A History of Biotechnology, Cambridge, MA: Cambridge University Press.
11. Bush, V. (1945), 'Science: the endless frontier', a report to the President on postwar scientific research, Washington, DC.
12. Carlsson B. (ed.) (1997), Technological Systems and Industrial Dynamics, Boston, MA: Kluwer Academic Publishers.
13. Carlsson, B. (ed.) (2002), Technological Systems in the Bio Industries: An International Study, Boston, MA: Kluwer Academic Publishers.
14. Casper, Steven and H. Kettler (2001), 'National institutional frameworks and the hybridization of entrepreneurial business models: the German and UK biotechnology sectors', Industry & Innovation, 8.
15. Cetindamar, D. and J. Laage-Hellman (2003), 'Growth dynamics in the biomedial/ biotechnology system', Small Business Economics, 20, 287-303.
16. Cockburn, I.M., R. Henderson and S. Stern (1999), 'The diffusion of science-driven drug discovery: organizational change in pharmaceutical research', NBER working paper, no. 7359, September.
17. Cockburn, I.M., R. Henderson and S. Stern (1999b), 'Balancing incentives: the tension between basic and applied research, NBER working paper, no. 6882.
18. Cohen, W., R. Nelson and J. Walsh (2002), 'Links and impacts: the influence of public research on industrial R&D', Management Science, 48(1), 1-23.
19. Collins, P. and S.Wyatt (1988), 'Citations in patents to the basic research literature', Research Policy, 17, 65-74.
20. Commission of the European Communities (2002), 'Life science and biotechnology - a strategy for Europe', communication from the commission to the council, the European parliament, the economic and social committee and the committee of the regions, 23 January.
21. Cooke, P. (2001), 'New economy innovation systems: biotechnology in Europe and the USA', Industry & Innovation, 8, 267-89
22. Cortright, J. and H. Mayer (2002), Signs of Life: The Growth of Biotechnology Centers in the U.S., Washington, DC: The Brookings Institution.
23. Crowther, S., M. Hopkins, P. Martin, E. Millstone, M. Sharp and P. van Zwanenberg (1999), 'Benchmarking innovation in modern biotechnology', report for the European Commission, DG III - Industry, 1999, Brighton: SPRU, University of Sussex.
24. De la Mothe J. and J. Niosi (eds) (2000), The Economic and Social Dynamics of Biotechnology, Boston, MA: Kluwer Academic Publishers.
25. DiMasi, J.A., R.W. Hansen and H.G. Grabowski (2003), 'The price of innovation: new estimates of drug development costs', Journal of Health Economics, 22, 151-85.
26. Dosi, G. (1988), 'Sources, procedures and microeconomic effects of innovation', Journal of Economic Literature, XXVI(3) 1120-71.
27. Dodgson, M. (1991a), 'Strategic alignment and organizational options in biotechnology firms', Technology Analysis and Strategic Management, 3(2), 115-26.
28. Dodgson, M. (1991b), The Management of Technological Learning: Lessons from a Biotechnology Company, Berlin and New York: Walter de Gruyter.
29. Downward, P., J. Finch and J. Ramsay (2003), 'Seeking a role for empirical analysis in critical realist explanation' in P. Downward (ed.), Applied Economics and the Critical Realist Critique, London: Routledge.
30. Edquist, C. and M. McKelvey (eds) (2000), Systems of Innovation: A Reference Collection, Cheltenham, UK and Northampton, MA, USA: Edward Elgar.
31. Eisenberg, R. (1996), 'Public research and private development: patents and technology transfer in government-sponsored research', Virginia Law Review, 1663-1727.
32. Eisenberg, R. (2001), 'Bargaining over the transfer of proprietary research tools: is this market emerging or failing?', in D. Dreyfuss and H. First (eds), Expanding the Bounds of Intellectual Property: Innovation Policy for the Knowledge Society, Oxford: Oxford University Press.
33. Fagerberg, J., D. Mowery and R. Nelson (eds) (forthcoming), Handbook of Innovation, Oxford: Oxford University Press.
34. Faulkner,W. and J. Senker (1995), Knowledge Frontiers: Public Sector Research and Industrial Innovation in Biotechnology, Engineering Ceramics and Parallel Computing, Oxford: Clarendon Press.
35. Feldman, M. (1994). The Geography of Innovation, Boston, MA: Kluwer Academic Publishers.
36. Fransman, M. (2001), 'Designing Dolly: interactions between economics, technology and science and the evolution of hybrid institutions', Research Policy, 30(2), 263-73.
37. Fuchs,G. (ed.) (2003), Biotechnology in Comparative Perspective, London:Routledge.
38. Gambardella, A. (1992), 'Competitive advantage from in-house scientific research: the US pharmaceutical industry in the 1980s', Research Policy, 21, 391-407.
39. Galambos L. and J. Sturchio (1998), 'Pharmaceutical firms and the transition to biotechnology: a study in strategic innovation', Business History Review, 72(2), 250-78.
40. Gault, F. and J. de la Mothe (eds) (2002), Alliances, Networks and Partnerships in the Innovation Process, Boston, MA: Kluwer Academic Publishers.
41. Genua, A. (1999), The Economics of Knowledge Production: Funding and the Structure of University Research. Cheltenham, UK and Northampton, MA, USA: Edward Elgar.
42. Giesecke, S. (2000), 'The contrasting role of government in the development of biotechnology industry in the US and Germany', Research Policy, 29(2), 205-23.
43. Grabowski H. and J. Vernon (1994), 'Innovation and structural change in pharmaceuticals and biotechnology', Industrial and Corporate Change, 3(3), 435-50.
44. Grant, R. (2002), Contemporary Strategy Analysis: Concepts, Techniques and Applications, Malden, MA: Blackwell Business.
45. Hansson, M.G. and M. Levin (eds) (2003), Biobanks as Resources for Health, Uppsala: Uppsala University.
46. Hara, T. (2003), Innovation in the Pharmaceutical Industry: The Process of Drug Discovery and Development, Cheltenham, UK and Northampton, MA, USA, Edward Elgar.
47. Harvey, M., S. Quilley and H. Beynon (2003), Exploring the Tomato: Transformations of Nature, Society and Economy, Cheltenham, UK and Northampton, MA, USA: Edward Elgar.
48. Henderson, R. (2000), 'Drug industry mergers won't necessarily benefit R&D', Research Technology Management, July/August, 10-11.
49. Henderson, R., L. Orsenigo and G. Pisano (1999), 'The pharmaceutical industry and the revolution in molecular biology: interactions among scientific, institutional and organizational change', in D. Mowery and R. Nelson (eds), Sources of Industrial Leadership: Studies of Seven Industries, Cambridge: Cambridge University Press, pp. 267-311.
50. Henrekson, M. and N. Rosenberg, (2000), Akademiskt entreprenörskap: universitet och näringsliv i samverkan (Academic Entrepreneurship: University and Industry in Collaboration), Stockholm: SNS Förlag.
51. Holmén, M. and M. McKelvey (2003), 'How to systematically study regional restructuration? IT and biotech case studies in Sweden', special issue of European Urban and Regional Studies Journal.
52. Horst, H. and A. Pyka (eds) (forthcoming), Companion on Neo-Schumpeterian Economics, Cheltenham, UK and Northampton, MA, USA: Edward Elgar.
53. Kay, L. (1993), The Molecular Vision of Life: Caltech, the Rockefeller Foundation, and the Rise of the New Biology, Oxford: Oxford University Press.
54. Kenney, M. (1986), Biotechnology: The University-Industry Complex, New Haven, CT: Yale University Press.
55. Kline, S. and N. Rosenberg (1986), 'An overview of innovation', in R. Lanau and N. Rosenberg, The Positive Sum Strategy: Harnessing Technology for Economic Growth, Washinton, DC: National Academy Press.
56. Kornberg, A. (1995), The Golden Helix: Inside Biotech Ventures, Sausalito, CA: University Science Books.
57. KSLAT (1997), Transgenic Animals and Food Production, Kungl: Skogs- och Lantbruksakademiens, 136 (20).
58. Kuhn, T. (1970), The Structure of Scientific Revolutions, 2nd edn, Chicago, IL: University of Chicago Press.
59. Laage-Hellman, J. (2003), 'Clinical genomics companies and biobanks: the use of biosamples in commercial research on the genetics of common diseases', in M.G. Hansson and M. Levin (eds), Biobanks as Resources for Health, Uppsala: Uppsala University, pp. 51-89.
60. Lawton-Smith, H. (2002) 'The biotechnology industry in Oxfordshire: dynamics of change', paper presented at workshop The Economics and Business of Bio-Sciences & Bio-Technologies: What can be learnt from the Nordic Countries and the UK?, Chalmers University of Technology, Gothenburg, 25-27 September.
61. Lemarié, S., V. Mangematin and A. Torré (2001), 'Is the creation and development of biotech SMEs localised?' Small Business Economics, 17, 61-76.
62. Liebeskind, J.P., A.L. Oliver, L. Zucker, and M. Brewer (1996), 'Social networks, learning, and flexibility: sourcing scientific knowledge in new biotechnology firms', Organization Science, 7(4), 428-43.
63. Lindblom, C. (1977), Politics and Markets: The World's Political-economic Systems, New York: Basic Books.
64. Luukkonen, T. (2002), 'Building competencies in biotechnology firms: the influence of firm age and origin on knowledge networks and business skills', paper presented at workshop The Economics and Business of Bio-Sciences & Bio-Technologies: What can be Learnt from the Nordic Countries and the UK?, Chalmers University of Technology, Gothenburg, Sweden, 25-27 September.
65. McKelvey, M. (1996a), Evolutionary Innovations: The Business of Biotechnology, Oxford: Oxford University Press.
66. McKelvey,M. (1996b), 'Discontinuities in genetic engineering for pharmaceuticals? Firm jumps and lock-in in systems of innovation', Technology Analysis & Strategic Management, 8(2).
67. McKelvey, M. (1996c), 'Redefining transfer in biotechnology and software: multiple creation of knowledge and issues of ownership', in A. Inzelt and R. Coenen (eds), Knowledge, Technology Transfer and Forecasting, Boston, MA: Kluwer Academic Publishers, pp. 33-47.
68. McKelvey,M. (1997a), 'Using evolutionary theory to define systems of innovation', in Charles Edquist (ed.), Systems of Innovation: Technology, Institutions and Organizations, Pinter/Cassell Publishers, pp. 200-22.
69. McKelvey,M. (1997b), 'Coevolution in commercial genetic engineering', Industrial and Corporate Change, 6(3), 503-32.
70. McKelvey, M. (1997c), 'Emerging environments in biotechnology', in H. Etzkowitz and L. Leydesdorff (eds), Universities and the Global Knowledge Economy: A Triple Helix of University-Industry-Government Relations, London: Pinter Publishers.
71. McKelvey, M. (2002), 'The economics of biotechnology', entry into The International Encyclopedia of Business and Management and entry into The Handbook of Economics, International Thompson Business Press.
72. McKelvey,M. (forthcoming), 'Biotechnology industries', in H. Horst and A. Pyka (eds), Companion on Neo-Schumpeterian Economics, Cheltenham, UK and Northampton, MA, USA: Edward Elgar.
73. McKelvey, M. and L. Orsenigo (2002), 'Biotech-Pharmaceuticals analysed as sectoral systems of innovation', extended report to the EU-funded ESSY Project, website www.cespri.it.
74. McKelvey, M., H. Alm and M. Riccaboni (2003), 'Does co-location matter for formal knowledge collaboration in the Swedish biotechnology-pharmaceutical sector?' Research Policy, 32, 483-501.
75. McKelvey,M. and L. Orsenigo (eds) (forthcoming), The Economics of Biotechnology: A Reference Collection, Cheltenham, UK and Northampton, MA, USA: Edward Elgar.
76. McKelvey, M, L. Orsenigo and F. Pammoli (forthcoming), 'Pharmaceuticals as a sectoral system of innovation', in F. Malerba (ed.) (2004), Sectoral Systems of Innovation, Cambridge: Cambridge University Press.
77. Malerba, F. and L. Orsenigo (2002), 'Innovation and market structure in the dynamics of the pharmaceutical industry and biotechnology: towards a historyfriendly model', Industrial and Corporate Change, 11(4), 667-703.
78. Malo, S. (2003), 'Coping with a turbulent environment through technological learning: the case of combinatorial chemistry', paper presented at the annual EAEME conference, April, arranged through the International Schumpeter Society Augsburg, Germany.
79. Mangematin,V., S. Lemarié, J. Boisson,D. Catherine, F. Corolleur,R. Coronini and M. Trommettter (2003), 'Sectoral systems of innovation: SME development and heterogenity of trajectories', Research Policy.
80. Mowery, D., R. Nelson, B. Sampat and A. Ziedonis (2001), 'The growth of patenting and licensing by U.S. Universities: an assessment of the effect of the Bayh-Dole Act of 1980', Research Policy, 30(1), 99-119.
81. Mowery, D. and B. Sampat (forthcoming), 'Universities in the national innovation system' in J. Fagerberg,D.Mowery and R. Nelson (eds), Handbook of Innovation, Oxford: Oxford University Press.
82. Narula, R. and A. Zanfei (forthcoming), 'The international dimension of innovation', in J. Fagerberg, D. Mowery and R. Nelson (eds), Handbook of Innovation, Oxford: Oxford University Press.
83. National Science Foundation (NSF) (2002), 'Changing composition of federal funding for research and development and R&D plant since 1990', InfoBrief NSF 02-315 April 2002, website www.nsf.gov/sbe/srs/infbrief/nsf02315/start.htm
84. National Institutes of Health (NIH) (2003), 'Summary of the FY 2004 President's budget', 3 February.
85. Nelson, R. and S. Winter (1982), An Evolutionary Theory of Economic Change, Cambridge, MA: Belknap Press of Harvard University Press.
86. Nesta, L. and P. Saviotti. (2003), 'Intangible assets and market value: evidence from biotechnology firms', paper presented at the Chalmers workshop Innovation and Entrepreneurship in IT/Telecommunication and in Biotech/ Pharmaceuticals,May.
87. Nightingale, P. (2000), 'Economies of scale in experimentation: knowledge and technology in pharmaceutical R&D', Industrial and Corporate Change, 9(2), 315-59.
88. Nilsson, A.S. (2001), 'Interaction between researchers, firms managers & venture capitalists: the essence of biotechnology business', PhD thesis, Stockholm, Karolinska Institutet, Sweden.
89. Niosi, J. (2003), 'Alliances are not enough: explaining rapid growth in biotechnology', Research Policy, 23(5), 737-50.
90. Nooteboom, B. (1999), Inter-Firm Alliances: Analysis and Design, London: Routledge.
91. OECD (Organisation for Economic Co-operation and Development) (1997), National Systems of Innovation, Paris: OECD.
92. OECD (1989), Biotechnology: Economic and Wider Impacts, Paris: OECD.
93. OTA (Office of Technology Assessment) (1984), Commercial Biotechnology: An International Analysis, OTA-BA-218, Washington, DC: US Congress.
94. OTA (1991), Biotechnology in a Global Economy, OTA-H-494, Washington, DC: US Congress.
95. OTA (1993), Pharmaceutical R&D: Costs, Risks and Rewards, OTA-H-522, Washington DC: US Congress.
96. Oliver, R. (1999), The Coming Biotech Age: The Business of Bio-Materials, New York: McGraw-Hill.
97. Orsenigo, L. (1989), The Emergence of Biotechnology: Institutions and Markets in the Industrial Innovation, London: Pinter Publishers.
98. Orsenigo, L., F. Pammolli and M. Riccaboni (2001), 'Technological change and network dynamics: Lessons from the pharmaceutical industry', Research Policy, 30, 485-508.
99. Orsenigo, L., F. Pammolli, M. Riccaboni, A. Bonaccorsi and G. Turchetti (1998), 'The evolution of knowledge and the dynamics of an industry network', Journal of Management and Governance, 1, 147-75.
100. Owen-Smith, J., M. Riccaboni, F. Pammolli and W.W. Powell. (2002), 'A comparison of US and European University-Industry relations in the life sciences', Management Science.
101. Persson, A. and S. Welin (2002), 'Swedish human embryonic stem cell research: issues in regulation and commercialization', paper presented at workshop The Economics and Business of Bio-Sciences & Bio-Technologies: What can be learnt from the Nordic Countries and the UK?, Chalmers University of Technology, Gothenburg, Sweden, 25-27 September.
102. Pisano, G. (1991), 'The governance of innovation: vertical integration and collaborative arrangements in the biotechnology industry', Research Policy, 20, 237-49.
103. Pisano, G. (1997), The Development Factory: Unlocking the Potential of Process Innovation, Boston, MA: Harvard Business School Press.
104. Pisano,G.P.,W. Shan and D.J. Teece (1988), 'Joint ventures and collaboration in the biotechnology industry', in D.C. Mowery (ed.), International Collaboration Ventures in US Manufacturing, Cambridge: Ballinger.
105. Powell,W.W. (1998), 'Learning from collaboration: knowledge and networks in the biotechnology and pharmaceutical industry', California Management Review, 40(3), 228-40.
106. Powell, W.W. and P. Brantley (1992), 'Competitive cooperation in biotechnology: learning through networks', in N. Nohria and R. Eccles (eds), Networks and Organizations, Boston, MA: Harvard Business School Press, pp. 366-94.
107. Powell,W.W., K.W. Koput and L. Smith-Doerr (1996), 'Interorganizational collaboration and the locus of innovation: networks of learning in biotechnology', Administrative Science Quarterly, 41(1), 116-45.
108. Powell, W.W. and J. Owen-Smith (1998), 'Universities and the market for intellectual property in the life sciences', Journal of Policy Analysis and Management, 17(2), 253-77.
109. Prevezer, M. (1997), 'The dynamics of industrial clustering in biotechnology', Small Business Economics, 9, 255-71.
110. Rabinow, P. (1996), Making PCR: A Story of Biotechnology, Chicago, IL: University of Chicago Press.
111. Red Herring (2000), 'Bioethically speaking: biotech companies navigate murky waters in the 21st century', April, pp. 294-95.
112. Rickne,A. (2000), 'New technology-based firms and industrial dynamics - evidence from the technological system of biomaterials in Sweden, Ohio and Massachusetts', doctoral thesis, Department of Industrial Dynamics, Chalmers University of Technology, Gothenburg, Sweden.
113. Rifkin, J. (1998), The Biotech Century: How Genetic Commerce Will Change the World, London: Phoenix.
114. Rothaermel, F.T. (2000), 'Technological discontinuities and the nature of competition', Technology Analysis & Strategic Management, 12(2)
115. Rynning, E. (2003), 'Public law aspects on the use of biobank samples: privacy versus the interests of research', in M.G. Hansson and M. Levin (eds), Biobanks as Resources for Health, Uppsala: Uppsala University, pp. 91-128.
116. Saviotti, P. (1999), 'Industrial structure and the dynamics of knowledge generation in biotechnology', in J. Senker (ed.), Biotechnology and Competitive Advantage, Cheltenham, UK and Northampton, MA, USA: Edward Elgar.
117. Senghaas, D. (1985), The European Experience: A Historical Critique of Development Theory, Dover, UK: Berg Publishers.
118. Senker, J. (ed.) (1999), Biotechnology and Competitive Advantage: Europe's Firms and the US Challenge, Cheltenham, UK and Northampton, MA, USA: Edward Elgar.
119. Senker, J. and M. Sharp (1997), 'Organizational learning in cooperative alliances: some case studies in biotechnology', Technology Analysis & Strategic Management, 9(1), 35-51.
120. Sharp, M. (1991), 'Pharmaceuticals and biotechnology: perspectives for the European industry', in C. Freeman, M. Sharp and W. Walker (eds), Technology and the Future of Europe: Global Competition and the Environment in the 1990s, London: Pinter Publishers.
121. Shaw, B. (1985), 'The role of the interaction between the user and the manufacturer in medical equipment innovation', R&D Management, 15(4), 283-92.
122. Shaw, B. (1990), 'Developing technological innovations within networks', Entrepreneurship & Regional Development, 3, 111-28.
123. Sorensen, O. and T. Stuart (2001), 'Syndication networks and the spatial distribution of venture capital investments', American Journal of Sociology.
124. Stankiewicz, Rikard (2002), 'The cognitive dynamics of biotechnology and the evolution of its technological systems', in Bo Carlsson (ed.), Technological Systems in the Bio Industries, Boston, MA: Kluwer Academic Publishers, pp. 35-52.
125. Swann, P., M. Prevezer and D. Stout (eds) (1999), The Dynamics of Industrial Clustering: International Companies in Computing and Biotechnology, Oxford: Oxford University Press.
126. Tapon, F. and C.B. Cadsby (1996), 'The optimal organization of research: evidence from eight case studies of pharmaceutical firms', Journal of Economic Behavior and Organization, 31, 381-99.
127. Tidd, J., J. Bessant and K. Pavitt (1997), Managing Innovation: Integrating Technological, Market and Organizational Change, Chichester: Wiley.
128. Wald, S. (1996), 'Introduction: on the pervasiveness of biotechnology', STI Review, 19, special issue on biotechnology.
129. Walsh, V., J. Niosi and P. Mustar (1995), 'Small firm formation in biotechnology: a comparison of France, Britain and Canada', Technovation, 15, 303-27.
130. Wedin, T. (2002), 'Combinatory resources and weak ties: the development of an investment network around the Stockholm-Uppsala biomedical sector', paper presented at workshop The Economics and Business of Bio-Sciences & Bio-Technologies: What can be learnt from the Nordic Countries and the UK?, Chalmers University of Technology, Gothenburg, Sweden, 25-27 September.
131. Wheale, P., R. von Schomberg and P. Glasner (eds) (1998), The Social Management of Genetic Engineering, Aldershot: Ashgate Publishing Company.
132. Wiendt, A. and N. Amin (1994), 'Biotechnology: the emerging battlefield for US and Japanese pharmaceutical companies', Technology Analysis & Strategic Management.
133. Whittaker, E. and J. Bower (1994), 'A shift to external alliances for product development in the pharmaceutical industry', R&D Management, 24(3).
134. Zucker, L., M. Darby and B. Brewer (1999), 'Intellectual human capital and the birth of the US Biotechnology Enterprise', American Economic Review, 88(1), 290-306.
135. Zucker, L., M. Darby and J. Armstrong (2002), 'Commercializing knowledge: university science, knowledge capture, and firm performance in biotechnology', Management Science, 48(1), 138-53.
136. Zeller, C. (2001), 'Clustering biotech: a recipe for success? Spatial patterns of growth of biotechnology in Munich, Rhineland and Hamburg, Small Business Economics, (17), 123-41.